Dr. Perez on the Potential Utility of KIN-2787 in BRAF-Mutated Solid Tumors

Supplements and Featured PublicationsEmerging Therapeutic Approaches to Target BRAF Mutations in Solid Tumors
Volume 1
Issue 1

In Partnership With:

Cesar Augusto Perez, MD, discusses the potential utility of KIN-2787 in BRAF-mutated solid tumors.

Cesar Augusto Perez, MD, medical oncologist, director, Drug Development, Florida Cancer Specialists & Research Institute, Sarah Cannon Research Institute, discusses the potential utility of KIN-2787 in BRAF-mutated solid tumors.

KIN-2787 is an investigational, next-generation, pan-RAF inhibitor being evaluated for patients with solid tumors harboring class I, II, and III BRAF mutations, Perez explains. The agent was specifically developed to target class II and III mutations, which is an area of significant unmet need in patients with BRAF-mutated cancers.

KIN-2787 is being evaluated in an ongoing phase 1 trial (NCT04913285) for adult patients with BRAF-mutated solid tumors, including non–small cell lung cancer and melanoma, Perez says. This drug is unique because most available agents for patients with BRAF-mutated diseases were designed to target class I mutations. As such, the results of this study will be intriguing as KIN-2787 could have clinical utility across BRAF mutation–positive subgroups, Perez concludes.

Related Videos
Sarah E. S. Leary, MD, MS, attending physician, medical director, Pediatric Brain Tumor Program, Seattle Children’s Hospital; professor, Department of Pediatrics, University of Washington School of Medicine
Rita Nanda, MD
Vikram Narayan, MD
Daniel Olson, MD
Vishal Patel, MD, FAAD, FACMS, associate professor, Dermatology, George Washington (GW) School of Medicine & Health Sciences
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute